These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

658 related articles for article (PubMed ID: 35912183)

  • 1. Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Psoriasis: A Systematic Review and Meta-Analysis of Observational Studies.
    Yu Y; Zhou Y; Zhang X; Tan K; Zheng J; Li J; Cui H
    Front Oncol; 2022; 12():934093. PubMed ID: 35912183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
    Yan YD; Cui JJ; Fu J; Su YJ; Chen XY; Gu ZC; Lin HW
    Front Immunol; 2021; 12():760737. PubMed ID: 34925331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicity spectrum of immunotherapy in advanced lung cancer: A safety analysis from clinical trials and a pharmacovigilance system.
    Yan YD; Zhao Y; Zhang C; Fu J; Su YJ; Cui XL; Ma EL; Liu BL; Gu ZC; Lin HW
    EClinicalMedicine; 2022 Aug; 50():101535. PubMed ID: 35812997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis.
    Zhao Q; Zhang J; Xu L; Yang H; Liang N; Zhang L; Zhang F; Zhang X
    Front Immunol; 2021; 12():730320. PubMed ID: 34646270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint inhibitors in first-line therapies of metastatic or early triple-negative breast cancer: a systematic review and network meta-analysis.
    Liang X; Chen X; Li H; Li Y
    Front Endocrinol (Lausanne); 2023; 14():1137464. PubMed ID: 37229447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint inhibitors therapies in patients with cancer and preexisting autoimmune diseases: A meta-analysis of observational studies.
    Xie W; Huang H; Xiao S; Fan Y; Deng X; Zhang Z
    Autoimmun Rev; 2020 Dec; 19(12):102687. PubMed ID: 33131688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review and meta-analysis of observational studies and uncontrolled trials reporting on the use of checkpoint blockers in patients with cancer and pre-existing autoimmune disease.
    Lopez-Olivo MA; Kachira JJ; Abdel-Wahab N; Pundole X; Aldrich JD; Carey P; Khan M; Geng Y; Pratt G; Suarez-Almazor ME
    Eur J Cancer; 2024 Aug; 207():114148. PubMed ID: 38834015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoint inhibitors in Cancer patients with rheumatologic preexisting autoimmune diseases: a systematic review and meta-analysis.
    Liu X; Li S; Ke L; Cui H
    BMC Cancer; 2024 Apr; 24(1):490. PubMed ID: 38632528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study.
    Tison A; Quéré G; Misery L; Funck-Brentano E; Danlos FX; Routier E; Robert C; Loriot Y; Lambotte O; Bonniaud B; Scalbert C; Maanaoui S; Lesimple T; Martinez S; Marcq M; Chouaid C; Dubos C; Brunet-Possenti F; Stavris C; Chiche L; Beneton N; Mansard S; Guisier F; Doubre H; Skowron F; Aubin F; Zehou O; Roge C; Lambert M; Pham-Ledard A; Beylot-Barry M; Veillon R; Kramkimel N; Giacchero D; De Quatrebarbes J; Michel C; Auliac JB; Gonzales G; Decroisette C; Le Garff G; Carpiuc I; Vallerand H; Nowak E; Cornec D; Kostine M;
    Arthritis Rheumatol; 2019 Dec; 71(12):2100-2111. PubMed ID: 31379105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy.
    Halle BR; Betof Warner A; Zaman FY; Haydon A; Bhave P; Dewan AK; Ye F; Irlmeier R; Mehta P; Kurtansky NR; Lacouture ME; Hassel JC; Choi JS; Sosman JA; Chandra S; Otto TS; Sullivan R; Mooradian MJ; Chen ST; Dimitriou F; Long G; Carlino M; Menzies A; Johnson DB; Rotemberg VM
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34635495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer.
    Cunningham-Bussel A; Wang J; Prisco LC; Martin LW; Vanni KMM; Zaccardelli A; Nasrallah M; Gedmintas L; MacFarlane LA; Shadick NA; Awad MM; Rahma O; LeBoeuf NR; Gravallese EM; Sparks JA
    Arthritis Rheumatol; 2022 Mar; 74(3):527-540. PubMed ID: 34397169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and risk factors of acute kidney injury in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Liu C; Wei W; Yang L; Li J; Yi C; Pu Y; Yin T; Na F; Zhang L; Fu P; Zhao Y
    Front Immunol; 2023; 14():1173952. PubMed ID: 37313406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy of Immune Checkpoint Inhibitors in Cancer Patients and Preexisting Autoimmune Disease: A Systematic Review and Meta-Analysis in Non-Small-Cell Lung Cancer.
    Aung WY; Lee CS; Morales J; Rahman H; Seetharamu N
    Clin Lung Cancer; 2023 Nov; 24(7):598-612. PubMed ID: 37328320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pancreatic adverse events of immune checkpoint inhibitors therapy for solid cancer patients: a systematic review and meta-analysis.
    Zhao Z; Zhang W; Pang L; Zeng L; Liu S; Liu J
    Front Immunol; 2023; 14():1166299. PubMed ID: 37359551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis.
    Zhou X; Yao Z; Yang H; Liang N; Zhang X; Zhang F
    BMC Med; 2020 Apr; 18(1):87. PubMed ID: 32306958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors.
    Nuzzo PV; Pond GR; Abou Alaiwi S; Nassar AH; Flippot R; Curran C; Kilbridge KL; Wei XX; McGregor BA; Choueiri T; Harshman LC; Sonpavde G
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32234849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune-related adverse events after immune checkpoint inhibitor exposure in adult cancer patients with pre-existing autoimmune diseases.
    Pizuorno Machado A; Shatila M; Liu C; Wang J; Altan M; Zhang HC; Thomas A; Wang Y
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):6341-6350. PubMed ID: 36752908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients.
    Song P; Zhang D; Cui X; Zhang L
    Thorac Cancer; 2020 Sep; 11(9):2406-2430. PubMed ID: 32643323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Safety of Immunosuppressants Used in the Treatment of Immune-Related Adverse Events due to Immune Checkpoint Inhibitors: a Systematic Review.
    Machado AP; Ratliff H; Abdelwahab A; Vohra MH; Kuang A; Shatila M; Khan MA; Shafi MA; Thomas AS; Philpott J; Alhalabi O; Wang Y
    J Cancer; 2023; 14(16):2956-2963. PubMed ID: 37859810
    [No Abstract]   [Full Text] [Related]  

  • 20. Multidisciplinary approach to treatment with immune checkpoint inhibitors in patients with HIV, tuberculosis, or underlying autoimmune diseases.
    Aguilar-Company J; Lopez-Olivo MA; Ruiz-Camps I
    Front Med (Lausanne); 2022; 9():875910. PubMed ID: 35911382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.